Document is current
Any future updates will be listed below
-
Authors
,
Snell, Kym I. E.
Allotey, John
Smuk, Melanie
Hooper, Richard
Chan, Claire
Ahmed, Asif
Chappell, Lucy C.
Von Dadelszen, Peter
Green, Marcus
Kenny, Louise
Khalil, Asma
Khan, Khalid S.
Mol, Ben W.
Myers, Jenny
Poston, Lucilla
Thilaganathan, Basky
Staff, Anne C.
Smith, Gordon C. S.
Ganzevoort, Wessel
Laivuori, Hannele
Odibo, Anthony O.
Arenas Ramírez, Javier
Kingdom, John
Daskalakis, George
Farrar, Diane
Baschat, Ahmet A.
Seed, Paul T.
Prefumo, Federico
da Silva Costa, Fabricio
Groen, Henk
Audibert, Francois
Masse, Jacques
Skråstad, Ragnhild B.
Salvesen, Kjell Å.
Haavaldsen, Camilla
Nagata, Chie
Rumbold, Alice R.
Heinonen, Seppo
Askie, Lisa M.
Smits, Luc J. M.
Vinter, Christina A.
Magnus, Per
Eero, Kajantie
Villa, Pia M.
Jenum, Anne K.
Andersen, Louise B.
Norman, Jane E.
Ohkuchi, Akihide
Eskild, Anne
Bhattacharya, Sohinee
McAuliffe, Fionnuala M.
Galindo, Alberto
Herraiz, Ignacio
Carbillon, Lionel
Klipstein-Grobusch, Kerstin
Yeo, Seon Ae
Browne, Joyce L.
Moons, Karel G. M.
Riley, Richard D.
Thangaratinam, Shakila
-
Funding
Funding for this research was provided by:
Health Technology Assessment Programme (14/158/02)
NIHR School for Primary Care Research
The UK Medical Research Council and Wellcome (102215/2/13/2)
- License Information
-
More Information
Article History
Received: 19 March 2020
Accepted: 26 August 2020
First Online: 2 November 2020
Ethics approval and consent to participate
: Not applicable. The study involved secondary analysis of existing anonymised data.
: Not applicable
: The authors disclose support from NIHR HTA for the submitted work. LCC reports being Chair of the HTA CET Committee from January 2019. AK reports being a member of the NIHR HTA board. BWM reports grants from Merck; personal fees from OvsEva, Merck, and Guerbet; and other from NHMRC, Guerbet, and Merch, outside the submitted work. GS reports grants and personal fees from GlaxoSmithKline Research and Development Limited, grants from Sera Prognostics Inc., non-financial support from Illumina Inc., and personal fees and non-financial support from Roche Diagnostics Ltd., outside the submitted work. JK reports personal fees from Roche Canada, outside the submitted work. JM reports grants from National Health Research and Development Program, Health and Welfare Canada, during the conduct of the study. JEN reports grants from Chief Scientist Office Scotland, other from GlaxoSmithKline and Dilafor, outside the submitted work. AG reports personal fees from Roche Diagnostics, outside the submitted work. IH reports personal fees from Roche Diagnostics and Thermo Fisher, outside the submitted work. RR reports personal fees from the BMJ, Roche, and Universities of Leeds, Edinburgh, and Exeter, outside the submitted work.
